Innovative Product Solution In The Angiotensin Receptor Blockers Market Industry Trends Gaining Momentum in the Global Angiotensin Receptor Blockers (ARBs) Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Angiotensin Receptor Blockers (ARBs) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Growth has been consistently noted in the angiotensin receptor blockers (arbs) market size in the past few years. The market will see an increase from $8.51 billion in 2024 to $8.78 billion in 2025, with a compound annual growth rate (CAGR) of 3.1%. Factors such as a hypertension epidemic, proven clinical efficiency, burden of cardiovascular disease, renal protection, established clinical guidelines, the role of ARBs as a primary treatment option, and cost-effectiveness have contributed to the growth seen in the historic period.

Angiotensin Receptor Blockers (ARBs) Market Size Forecast: What's the Projected Valuation by 2029?
The market for angiotensin receptor blockers (arbs) is projected to experience consistent expansion in the coming years, reaching a valuation of $10.52 billion by 2029 with a compound annual growth rate (CAGR) of 4.6%. The predicted growth during the forecast period can be associated with several factors including precision medicine initiatives, emphasis on combination therapies, the worldwide market expansion, utilization of biomarker-based treatments, government support, and heightened awareness about hypertension. Future market trends are expected to encompass the adoption of telemedicine, investment in research and development, competition from generics and impending patent expirations, the integration of digital health solutions to maintain medication adherence, along with the emergence of biosimilar competitors.

View the full report here:
https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

What Are the Drivers Transforming the Angiotensin Receptor Blockers (ARBs) Market?
The angiotensin receptor blockers market is predicted to expand due to the rising prevalence of cardiovascular diseases. Cardiovascular disease, which includes any disorder that impacts the heart or blood vessels, is often linked with the buildup of fatty deposits in the arteries (atherosclerosis) and a higher probability of clotting. Angiotensin receptor blockers can aid in reducing blood pressure and enhancing the heart's ability to circulate blood by facilitating the relaxation of veins and arteries, thereby reducing the chances of cardiovascular disease. For example, the American College of Cardiology, a professional medical organization based in the United States, predicted in August 2022 that the incidence of cardiovascular risk factors and disease would dramatically increase in the United States by 2060. As a result, the rising occurrence of cardiovascular diseases is spurring the expansion of the angiotensin receptor blockers market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Angiotensin Receptor Blockers (ARBs) Market?
Key players in the angiotensin receptor blocker market are innovating with advanced products such as angiotensin receptor neprilysin inhibitors, to enhance treatments and optimize patient outcomes in the realm of cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) are a group of drugs primarily utilised in treating heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical company based in India, rolled out sacubitril + valsartan tablets in January 2023. These tablets are dedicated to treating heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This drug combination belongs to the ARNI (angiotensin receptor neprilysin inhibitors) medication group. Sacubitril amplifies the natriuretic peptide (NP) system, which reduces fluid overload and encourages blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS) to decrease blood pressure and lighten the heart's workload. Together, they provide an effective improvement of heart failure symptoms, reduce the risk of cardiovascular death, and minimize the likelihood of hospital admission due to heart failure. These are sold under the brand name Sacu V.

Which Segments in the Angiotensin Receptor Blockers (ARBs) Market Offer the Most Profit Potential?
The angiotensin receptor blockers (arbs) market covered in this report is segmented -

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Which Firms Dominate the Angiotensin Receptor Blockers (ARBs) Market by Market Share and Revenue in 2025?
Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Which Regions Offer the Highest Growth Potential in the Angiotensin Receptor Blockers (ARBs) Market?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.